PREVENT Cancer Preclinical Drug Development Program (PREVENT)

Image of a scientist preparing genetic samples.

PREVENT supports the preclinical development of innovative cancer prevention interventions and biomarkers towards clinical applications. PREVENT provides NCI contract resources and expertise to generate data and/or materials needed for agent development instead of direct funding. The program is focused on unmet research needs that are not adequately addressed by the private sector. PREVENT’s current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.

Read more About PREVENT.

 

Application Instructions

Submission deadlines occur twice per year on the first Monday in February and September.

NEXT Deadline: February 3, 2020

Instructions for Applying
The application template was updated on 09/12/2017.

Supported Projects

95 Projects from PREVENT Cycles 1 through 16: 

  • 59 chemoprevention projects
  • 28 immunoprevention projects
  • 8 biomarker projects

More on each project and the supported prevention approaches

Available Resources

  • Efficacy and Intermediate Endpoint Biomarker Work
  • Toxicology and Pharmacology Testing
  • Prime Contractors 2019-2023

View Available Resources

Program Administration

  • Governance Structure
  • Intellectual Property Considerations
  • Data Access

Learn more about Program Administration